[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349241-105":59,"doc-detail-349241-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","long-term-chemotherapy-induced-peripheral-neuropathy-evaluated-using-patient-reported-outcomes-in-gynecologic-malignancies","Long-term chemotherapy-induced peripheral neuropathy evaluated using patient-reported outcomes in gynecologic malignancies","","Chemotherapy-induced peripheral neuropathy (CIPN) remains a clinically significant long-term challenge for gynecologic cancer survivors, yet durable outcomes have been insufficiently characterized. This study evaluates the long-term CIPN course after paclitaxel and carboplatin (TC) therapy using patient-reported outcomes. Participants with multiple gynecologic malignancies were assessed with the FACT/GOG Ntx neurotoxicity subscale and physician-rated NCI-CTCAE.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/long-term-chemotherapy-induced-peripheral-neuropathy-evaluated-using-patient-reported-outcomes-in-gynecologic-malignancies/349241/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/long-term-chemotherapy-induced-peripheral-neuropathy-evaluated-using-patient-reported-outcomes-in-gynecologic-malignancies/349241.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study objective regarding CIPN outcomes?","Question",{"text":112,"@type":113},"To evaluate the long-term outcomes of chemotherapy-induced peripheral neuropathy associated with paclitaxel and carboplatin using patient-reported outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was CIPN assessed in the study?",{"text":117,"@type":113},"CIPN was assessed using patient-reported outcomes with the FACT/GOG Ntx neurotoxicity subscale, and physicians also assessed it using NCI-CTCAE.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about long-term CIPN after TC therapy?",{"text":121,"@type":113},"After TC therapy, CIPN scores decreased over time, but five years after treatment initiation they remained significantly higher than in the follow-up without chemotherapy group, suggesting incomplete resolution.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349241,1790803619,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","J Gynecol Oncol. 2026 May;37(3):e54 [https://doi.org/10.3802/jgo.2026.37.e54](https://doi.org/10.3802/jgo.2026.37.e54)[ ](https://doi.org/10.3802/jgo.2026.37.e54)pISSN 2005-0380·eISSN 2005-0399  \nOriginal Article  \nReceived: Jan 18, 2025  \nRevised: May 21, 2025  \nAccepted: Sep 21, 2025  \nPublished online: Jan 16, 2026  \nCorrespondence to  \nHiroshi Tanabe  \nDepartment of Obstetrics and Gynecology, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan.  \nEmail: [htanabe@jikei.ac.jp](htanabe@jikei.ac.jp)  \n© 2026. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nChikage Narui  [https://orcid.org/0000-0003-3368-0359](https://orcid.org/0000-0003-3368-0359)[ ](https://orcid.org/0000-0003-3368-0359)Hiroshi Tanabe  [https://orcid.org/0000-0002-1301-719X](https://orcid.org/0000-0002-1301-719X)[ ](https://orcid.org/0000-0002-1301-719X)Masataka Takenaka  [https://orcid.org/0000-0002-3833-4730](https://orcid.org/0000-0002-3833-4730)[ ](https://orcid.org/0000-0002-3833-4730)Chihiro Sato  [https://orcid.org/0009-0004-9400-1924](https://orcid.org/0009-0004-9400-1924)[ ](https://orcid.org/0009-0004-9400-1924)Aikou Okamoto  [https://orcid.org/0000-0002-5079-0464](https://orcid.org/0000-0002-5079-0464)  \nLong-term chemotherapy-induced peripheral neuropathy evaluated using patient-reported outcomes in gynecologic malignancies  \nChikage Narui ,1 Hiroshi Tanabe ,1,2 Masataka Takenaka ,1 Chihiro Sato ,1 Aikou Okamoto  1  \n1Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan 2Department of Gynecology, National Cancer Center Hospital East, Chiba, Japan  \nABSTRACT  \nObjective: Chemotherapy-induced peripheral neuropathy (CIPN) poses a significant challenge for gynecological cancer survivors. However, information on its long-term outcomes remains limited. Recently, patient-reported outcomes (PROs), by which patients assess cancer treatment-related side effects, have been developed. This study aimed to evaluate the long-term outcomes of CIPN associated with paclitaxel and carboplatin (TC) therapy using PRO.  \nMethods: Patients with ovarian, corpus uteri, cervical, and other gynecological cancers who underwent surgery were included in the study, regardless of receiving postoperative chemotherapy. Patients with recurrent cancer were excluded. CIPN was assessed via PROs using the Functional Assessment of Cancer Therapy/Gynecologic Oncology GroupNeurotoxicity (FACT/GOG Ntx) subscale. The physicians assessed CIPN using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) .  \nResults: Of the 616 patients, 304 who received TC therapy (TC group) and 312 who were followed up without chemotherapy (NC group) were evaluated. Using the FACT/GOG Ntx subscale, the weighted mean of total score in the TC group was 8.2 in the first year, which significantly decreased over time (p\u003C0.001). However, 5 years after initiating treatment, the scores in the TC group remained significantly higher than did those in the NC group (p=0.040). Similar trends were found using the NCI-CTCAE evaluations.  \nConclusion: Following TC therapy, CIPN might improve over time. However, it might not resolve completely.  \nKeywords: Antineoplastic Agents; Female Genital Neoplasms; Gynecology; Patient Reported Outcome Measures; Peripheral Nervous System Diseases  \nSynopsis  \nLong-term chemotherapy-induced peripheral neuropathy (CIPN) outcomes were assessed using patient-reported outcomes. CIPN gradually improves over time afte","cbCaitz79GJcyN5K","https://ap.wps.com/l/cbCaitz79GJcyN5K","pdf",1838918,11,"English","## Objective\n## Methods\n## Results\n## Conclusion\n## Keywords","[{\"question\":\"What was the study objective regarding CIPN outcomes?\",\"answer\":\"To evaluate the long-term outcomes of chemotherapy-induced peripheral neuropathy associated with paclitaxel and carboplatin using patient-reported outcomes.\"},{\"question\":\"How was CIPN assessed in the study?\",\"answer\":\"CIPN was assessed using patient-reported outcomes with the FACT/GOG Ntx neurotoxicity subscale, and physicians also assessed it using NCI-CTCAE.\"},{\"question\":\"What did the results show about long-term CIPN after TC therapy?\",\"answer\":\"After TC therapy, CIPN scores decreased over time, but five years after treatment initiation they remained significantly higher than in the follow-up without chemotherapy group, suggesting incomplete resolution.\"}]","Long-term chemotherapy-induced peripheral neuropathy evaluated using patient-reported outcomes in gynecologic malignancies | PDF",1790082360,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49595c51b8f90c4d79a062b8a8ffe259.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42281c2c31f60c4ae082c71b1f9b8f70.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c6c3f93ecaba51ded3ccb48e3192bdc.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7db05b9f92778c69e9badd7b44857932.webp",980,1306]